Brand names: Bivigam
Human Immunoglobulin G · Antigen Neutralization
Route: Intravenous
FDA Black Box Warning
WARNING: THROMBOSIS, RENAL DYSFUNCTION AND ACUTE RENAL FAILURE Thrombosis may occur with immune globulin (IGIV) products, including BIVIGAM. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors. (see Warnings and Precautions [5.1] , Patient Counseling Information [17.2] ). Use of Immune Globulin Intravenous (IGIV) products, particularly those containing sucrose, has been reported to be associated with renal dysfunction, acute renal failure, osmotic nephrosis, and death 1,2 . Patients at risk of acute renal failure include those with any degree of pre-existing renal insufficiency, diabetes mellitus, advanced age (above 65 years of age), volume depletion, sepsis, paraproteinemia, or receiving known nephrotoxic drugs ( see Warnings and Precautions [5.3] ) . Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. BIVIGAM does not contain sucrose. For patients at risk of thrombosis, renal dysfunction or renal failure, administer BIVIGAM at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity ( see Dosage and Administration [2.2 , 2.3] , Warnings and Precautions [5.3] ). WARNING: THROMBOSIS, RENAL DYSFUNCTION AND ACUTE RENAL FAILURE See full prescribing information for complete boxed warning. Thrombosis may occur with immune globulin intravenous (IGIV) products, including BIVIGAM. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, a history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity and cardiovascular risk fac
Contraindications
4 CONTRAINDICATIONS BIVIGAM is contraindicated in patients who have had an anaphylactic or severe systemic reaction to the administration of human immune globulin. BIVIGAM is contraindicated in IgA deficiency patients with antibodies to IgA and a history of hypersensitivity. History of anaphylactic or severe systemic reactions to human immunoglobulin. [4] IgA deficient patients with antibodies to IgA and a history of hypersensitivity. [4 , 5.2]
Pregnancy & Breastfeeding
8.1 Pregnancy No human data are available to indicate the presence or absence of drug-associated risk. Animal reproductive studies have not been conducted with BIVIGAM. It is not known whether BIVIGAM can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Immune globulins cross the placenta from maternal circulation increasingly after 30 weeks of gestation. BIVIGAM should be given to pregnant women only if clearly needed. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.
4 interactions on record
VIGIV may impair efficacy of live attenuated measles vaccine. Defer vaccination until approximately three months after VIGIV administration or revaccinate three months after VIGIV if vaccinated shortly before.
Source: NLP:vaccinia immune globulin intravenous (human)
VIGIV may impair efficacy of live attenuated mumps vaccine. Defer vaccination until approximately three months after VIGIV administration or revaccinate three months after VIGIV if vaccinated shortly before.
Source: NLP:vaccinia immune globulin intravenous (human)
VIGIV may impair efficacy of live attenuated rubella vaccine. Defer vaccination until approximately three months after VIGIV administration or revaccinate three months after VIGIV if vaccinated shortly before.
Source: NLP:vaccinia immune globulin intravenous (human)
VIGIV may impair efficacy of live attenuated varicella vaccine. Defer vaccination until approximately three months after VIGIV administration or revaccinate three months after VIGIV if vaccinated shortly before.
Source: NLP:vaccinia immune globulin intravenous (human)